This study investigates if different diabetic treatment regimens affect diabetic foot ulcer healing. From
Diabetes affects approximately 29 million people in the US in 2014. 1 Impaired wound healing is a critical problem in diabetes that affects 1-4% of patients with diabetes annually. 2 The mechanisms of poor healing in diabetic foot ulcer are not fully understood. However, studies suggest that impaired leukocyte function, cytokines and growth factors dysregulation, neuropathy, and vasculopathy have important roles in nonhealing diabetic foot ulcers. 3, 4 According to CDC, 6 million patients use insulin to control their diabetes. 1 Besides controlling glucose levels, insulin has been shown to have wound healing effects. 5 The objective of this study is to evaluate the effects of systemic insulin treatment on healing of foot ulcers.
METHODS

Study subjects
The protocol was approved by Institutional Review Board of Oregon Health and Science University. This was a retrospective study of 85 subjects who were referred for treatment of diabetic foot ulcer to the vascular surgery clinic between January 2013 and December 2014 were included. Demographic information, medical history, imaging data, current medication, and foot and ulcer characteristics were obtained from the patients' medical records. All patients' information was recorded at the time of entry into clinic and prescribed by patients' primary care physician or an endocrinologist. The ulcers were followed until complete healing, amputation or until last clinical follow-up.
Definitions
Outcomes were divided into complete wound healing, minor amputation, major amputation, and chronic wounds. Ulcers that did not reach complete healing or amputation during the follow-up were considered chronic wounds. Amputations below the ankle were classified as minor amputations and amputations higher than this level were defined as major amputations.
Treatment for blood glucose control was divided into insulin and noninsulin therapy. Insulin therapy was defined as the presence of insulin on the medications list at the time of admission.
Statistical analysis
Data were summarized as median (min-max) for numerical measures and frequency (%) for categorical variables. Comparisons of frequencies between two groups were done by v 2 test and Fisher's exact test.
Uni-and multivariate binary logistic regression models were used to assess the association of insulin therapy with complete healing of the ulcers. Because more than one ulcer was studied in some of the patients, there was a possibility of predisposition in the subjects themselves for one particular outcome (endogenous patient effect). To cope with this issue, we used random-effect logistic regression models for longitudinal (panel) data with considering patient-specific ID as the cluster (patient-identifying) variable.
In regression models, the univariate model was considered as model 1, and model 2 was adjusted for wound characteristics (infection, affected limb, presence of Charcot's deformity, gangrene, and osteomyelitis on x-ray) and the patient's characteristics and comorbid conditions (age, gender, smoking status, type of diabetes, hypertension, chronic kidney disease, and peripheral arterial disease). Model 3 was further adjusted for serum hemoglobin A1C levels.
RESULTS
A total of 107 ulcers in 85 patients included in this study. Table 1 demonstrates a summary of baseline characteristics of the patients and ulcers. The subjects' median age on referral was 60.0 years (range: 31.1-90.1 years), and 58 (68.2%) cases were males. The diabetes type was type 2 in 70 (82.3%) of the patients. Insulin treatment was a part of diabetes management in 52 (61.2%) cases. The median serum hemoglobin A1C on all referrals was 7.9% (range: 4.9-17.6%). Hemoglobin A1C levels were actually higher in the insulin treated group than in the noninsulin-treated group (8.54 6 2.36 vs. 7.70 6 2.33). The ulcers were complicated with peripheral arterial disease in 24 (28.2%), Charcot's deformity in 8 (7.5%), infection in 54 (50.5%) and gangrene in 42 (39.2%) cases. Osteomyelitis was detected on x-ray imaging in 26 (25.5%) wounds. Final outcome was complete healing in 24 (22.4%), minor amputation in 50 (46.7%), major amputation in 11 (10.3%) wounds, and 22 (20.6%) of the ulcers did not heal during the observation period (chronic). The median time-tooutcome was 1.1 months, and the median follow-up time in chronic wound group was 6.0 months (range: 0.7-21.8 months). Among the patients who were receiving insulin treatment, 20 ulcers (30.3%) had complete healing compared to 4 (9.8%) among those who were treated with oral medication only or were not treated for diabetes at all (p 5 0.013) (Figure 1) . Table 2 demonstrates the results of random effect panel binary regression model. Insulin treatment was significantly associated with higher rates of complete wound healing in all models. Even after adjusting for serum hemoglobin A1C levels, insulin therapy was independently associated with complete healing of the ulcers (beta coefficient: 13.69, p 5 0.047). In multivariate model (model 3), higher levels of serum hemoglobin A1C (beta: 24.75, p 5 0.029) and presence of infection (beta: 214.63, p 5 0.012) were also significantly associated with lower rates of complete wound healing beside insulin treatment.
On sub-population analysis, after excluding subjects with minor amputation (n 5 50), insulin therapy was associated with higher rate of complete healing versus major amputation or development of a chronic wound (p 5 0.013, v 2 test) ( Figure 2 ). In regression model analysis, adjusted for insulin treatment and serum hemoglobin A1C levels, insulin therapy remained an independent predictor of complete healing (OR: 9.90, p 5 0.008).
DISCUSSION
The results of our study indicated that after adjusting for multiple confounding covariates, insulin therapy positively affects wound healing in people with diabetes.
It has been demonstrated that different glucose-lowering medications have promising effects on diabetic wound healing mainly through decreasing inflammation and promoting healing. 6 The idea of application of insulin in favor of wound healing was presented for the first time in 1930 by Joseph in a case series of complicated bed sore patients. 7 Later in 1968 Rosenthal in an experimental study showed that insulin-treated rats had increasingly higher tensile strengths of wounds compared to their nontreated controls. 8 Pierre in 1998 has shown using systemic insulin in patients with burns improves wound matrix formation. 9 More recently topical application of insulin has been shown to accelerate healing of diabetic ulcers 10, 11 ; however, its mechanism was not fully understood. Although effect of insulin was ascribed to its glucose control properties, 12 later studies revealed different mechanisms through which insulin improves wound healing. 13, 14 In our study using systemic insulin therapy was associated with higher rates of complete wound healing even after adjusting for multiple confounding covariate, including blood glucose control. The independent association of insulin therapy with higher rates of complete wound healing contends mechanisms other than Insulin therapy and diabetic foot ulcer Vatankhah et al.
blood glucose control for insulin. Increased microvessel density and growth of granulation tissue has been reported in patients with diabetic foot ulcers after topical injection of insulin compared to control group. 15 Topical insulin may improve wound healing even in healthy animals, reduce the duration of the inflammatory phase, and improve wound reepithelialization.
14 Topical insulin may accelerate healing of diabetic and nondiabetic wounds by enhancing the serine-threonine kinase (AKT) and extracellular signalregulated kinase (ERK) pathways and increased expression of endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF), and stromal cell-derived factor (SDF-1alpha).
11 A novel combination of negative pressure wound therapy and continuous-instillation of insulin as "wound chemotherapy" has shown promising results in a case of severe diabetic foot ulcer. 16 As strengths, our study is the first population-based study to show the effects of systemic insulin treatment on diabetic wound healing. Also long duration of follow-up assures precise categorization of nonhealing wound types. Additionally, adjusting statistical models for a broad range of potentially confounding factors including inherent patient effect increases the validity of the observed independent associations.
As limitations, our study is a retrospective cross-sectional study which challenges the evaluation of cause-and-effect associations. Although, the latency of the outcome measurement (foot ulcer healing) relative to the exposure (insulin treatment) assures the cause-and-effect nature of the observed association, still prospective blinded studies are required to evaluate the efficacy of systemic insulin treatment in diabetic wound healing. Also, the retrospective nature of this study also made it difficult to determine the cause of using insulin or other medications to control hyperglycemia and why HbA1C levels were not being properly managed at the time of admission and data entry. Therefore, the confounding effect of differences in later treatment for blood glucose control cannot be determined from this study.
In summary, systemic insulin treatment can improve wound healing in diabetic ulcers after adjusting for multiple confounding covariates. Future prospective clinical studies are required to more elucidate this association.
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